Fennec Pharmaceuticals Inc. (FRX.TO)
CAD 8.12
(-6.34%)
CAD 8.12
(-6.34%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.60 USD | 34.07% |
| 2022 | -0.91 USD | -35.82% |
| 2021 | -0.67 USD | 11.84% |
| 2020 | -0.76 USD | -20.63% |
| 2019 | -0.63 USD | -21.15% |
| 2018 | -0.52 USD | -10.64% |
| 2017 | -0.47 USD | -113.64% |
| 2016 | -0.22 USD | -261.25% |
| 2015 | -0.06 USD | 72.32% |
| 2014 | -0.22 USD | -215.79% |
| 2013 | 0.19 USD | 130.16% |
| 2012 | -0.63 USD | -206.78% |
| 2011 | 0.59 USD | 153.15% |
| 2010 | -1.11 USD | -13.27% |
| 2009 | -0.98 USD | 77.88% |
| 2008 | -4.43 USD | 7.32% |
| 2007 | -4.78 USD | 71.41% |
| 2006 | -16.72 USD | 18.24% |
| 2005 | -20.45 USD | 0.0% |
| 2003 | -15.04 USD | 24.23% |
| 2002 | -19.85 USD | -2.74% |
| 2001 | -19.32 USD | 3.98% |
| 2000 | -20.12 USD | -575.17% |
| 1999 | -2.98 USD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -0.20 USD | -142.55% |
| 2024 Q1 | 0.47 USD | 570.0% |
| 2023 Q3 | -0.07 USD | 66.38% |
| 2023 Q1 | -0.23 USD | 11.54% |
| 2023 Q2 | -0.21 USD | 8.7% |
| 2023 Q4 | -0.10 USD | -41.64% |
| 2023 FY | - USD | 34.07% |
| 2022 Q4 | -0.26 USD | 16.13% |
| 2022 Q1 | -0.15 USD | 11.76% |
| 2022 FY | - USD | -35.82% |
| 2022 Q3 | -0.31 USD | -63.16% |
| 2022 Q2 | -0.19 USD | -26.67% |
| 2021 Q2 | -0.15 USD | 16.67% |
| 2021 Q3 | -0.16 USD | -6.67% |
| 2021 Q4 | -0.17 USD | -6.25% |
| 2021 FY | - USD | 11.84% |
| 2021 Q1 | -0.18 USD | -50.0% |
| 2020 Q3 | -0.24 USD | -14.29% |
| 2020 Q1 | -0.19 USD | -5.56% |
| 2020 Q4 | -0.12 USD | 50.0% |
| 2020 FY | - USD | -20.63% |
| 2020 Q2 | -0.21 USD | -10.53% |
| 2019 Q1 | -0.13 USD | 13.33% |
| 2019 Q3 | -0.09 USD | 62.13% |
| 2019 Q2 | -0.24 USD | -84.62% |
| 2019 FY | - USD | -21.15% |
| 2019 Q4 | -0.18 USD | -98.02% |
| 2018 Q2 | -0.14 USD | -64.51% |
| 2018 Q3 | -0.14 USD | 0.0% |
| 2018 Q4 | -0.15 USD | -7.14% |
| 2018 Q1 | -0.09 USD | 29.08% |
| 2018 FY | - USD | -10.64% |
| 2017 FY | - USD | -113.64% |
| 2017 Q2 | -0.11 USD | -83.33% |
| 2017 Q4 | -0.12 USD | 20.0% |
| 2017 Q3 | -0.15 USD | -36.36% |
| 2017 Q1 | -0.06 USD | 31.03% |
| 2016 Q4 | -0.09 USD | -136.41% |
| 2016 FY | - USD | -261.25% |
| 2016 Q1 | -0.04 USD | 19.03% |
| 2016 Q3 | -0.04 USD | 34.87% |
| 2016 Q2 | -0.06 USD | -41.25% |
| 2015 Q1 | 0.02 USD | -94.12% |
| 2015 Q3 | -0.01 USD | 29.38% |
| 2015 Q4 | -0.05 USD | -337.17% |
| 2015 Q2 | -0.02 USD | -180.0% |
| 2015 FY | - USD | 72.32% |
| 2014 Q1 | -0.33 USD | -222.22% |
| 2014 Q4 | 0.34 USD | 750.0% |
| 2014 Q2 | -0.08 USD | 75.76% |
| 2014 Q3 | 0.04 USD | 150.0% |
| 2014 FY | - USD | -215.79% |
| 2013 Q3 | -0.21 USD | -126.92% |
| 2013 Q4 | 0.27 USD | 228.57% |
| 2013 FY | - USD | 130.16% |
| 2013 Q2 | 0.78 USD | 259.18% |
| 2013 Q1 | -0.49 USD | 37.18% |
| 2012 Q1 | 0.33 USD | -65.26% |
| 2012 Q3 | -0.09 USD | -26.88% |
| 2012 Q4 | -0.78 USD | -756.2% |
| 2012 FY | - USD | -206.78% |
| 2012 Q2 | -0.07 USD | -121.76% |
| 2011 FY | - USD | 153.15% |
| 2011 Q4 | 0.95 USD | 282.69% |
| 2011 Q3 | -0.52 USD | -1153.01% |
| 2011 Q2 | -0.04 USD | -106.01% |
| 2011 Q1 | 0.69 USD | 171.88% |
| 2010 Q1 | -0.12 USD | -4037.93% |
| 2010 FY | - USD | -13.27% |
| 2010 Q4 | -0.96 USD | -633.33% |
| 2010 Q3 | 0.18 USD | 0.0% |
| 2010 Q2 | - USD | 100.0% |
| 2009 FY | - USD | 77.88% |
| 2009 Q4 | -0.00 USD | 74.56% |
| 2009 Q3 | -0.01 USD | 96.32% |
| 2009 Q2 | -0.31 USD | 57.53% |
| 2009 Q1 | -0.73 USD | 14.12% |
| 2008 Q2 | -1.12 USD | 20.0% |
| 2008 Q1 | -1.40 USD | -42.86% |
| 2008 FY | - USD | 7.32% |
| 2008 Q4 | -0.85 USD | 19.81% |
| 2008 Q3 | -1.06 USD | 5.36% |
| 2007 FY | - USD | 71.41% |
| 2007 Q4 | -0.98 USD | 5.77% |
| 2007 Q1 | -2.01 USD | 37.96% |
| 2007 Q2 | -1.05 USD | 47.76% |
| 2007 Q3 | -1.04 USD | 0.95% |
| 2006 Q4 | -3.24 USD | 21.74% |
| 2006 FY | - USD | 18.24% |
| 2006 Q3 | -4.14 USD | -11.29% |
| 2006 Q2 | -3.72 USD | -7.83% |
| 2006 Q1 | -3.45 USD | 50.36% |
| 2005 Q3 | -4.45 USD | 15.72% |
| 2005 Q2 | -5.28 USD | -48.31% |
| 2005 Q1 | -3.56 USD | 0.0% |
| 2005 Q4 | -6.95 USD | -56.18% |
| 2005 FY | - USD | 0.0% |
| 2004 Q1 | -0.64 USD | 32.63% |
| 2004 Q3 | -3.32 USD | -8.5% |
| 2004 Q2 | -3.06 USD | -378.13% |
| 2003 Q2 | -1.09 USD | -23.86% |
| 2003 FY | - USD | 24.23% |
| 2003 Q4 | -0.95 USD | -15.85% |
| 2003 Q3 | -0.82 USD | 24.77% |
| 2003 Q1 | -0.88 USD | -14.29% |
| 2002 Q3 | -1.16 USD | 22.67% |
| 2002 Q2 | -1.50 USD | -63.04% |
| 2002 Q1 | -0.92 USD | -64.29% |
| 2002 FY | - USD | -2.74% |
| 2002 Q4 | -0.77 USD | 33.62% |
| 2001 Q2 | -0.71 USD | 33.02% |
| 2001 FY | - USD | 3.98% |
| 2001 Q4 | -0.56 USD | 37.78% |
| 2001 Q3 | -0.90 USD | -26.76% |
| 2001 Q1 | -1.06 USD | -17.78% |
| 2000 FY | - USD | -575.17% |
| 2000 Q3 | -1.11 USD | 0.0% |
| 2000 Q4 | -0.90 USD | 18.92% |
| 1999 FY | - USD | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Appili Therapeutics Inc. | -0.03 CAD | -1823.077% |
| Eupraxia Pharmaceuticals Inc. | -1.58 CAD | 62.025% |
| Helix BioPharma Corp. | -0.21 CAD | -185.714% |
| Microbix Biosystems Inc. | -0.00 CAD | -199900.0% |
| Medicenna Therapeutics Corp. | -0.37 CAD | -62.162% |
| Satellos Bioscience Inc. | -0.18 CAD | -233.333% |
| Oncolytics Biotech Inc. | -0.41 CAD | -46.341% |
| Sernova Corp. | -0.13 CAD | -361.538% |